A Clinical Study of Carboplatin plus Docetaxel in Patients with Metastatic Hormone-refractory Prosta

• 作 者: IshunGo;KatsuyukiKuratsukuri;TomoakiTanaka;JunjiUchida;RikioYoshimura;HidenoriKawashima;TatsuyaNakatani;
• 机 构: Department of Urology Bellland General Hospital Japan
• 出 处: BIT Life Sciences' 1st Annual World Cancer Congess-2008(
• 发表日期: 2008年期

　　Objectives: Prostate cancer is the second leading cause of cancer mortality among men in the U.S.To the authorsknowledge, there was no improved, second-line therapy for metastatic hormone refractory prostate cancer (HRPC).Recent data suggest that docetaxel-based chemotherapy has be effective in HRPC.Combination chemotherapy using carboplatin and weekly docetaxel was examined in Japanese patients with metastatic HRPC.Methods: Eligible men had metastatic prostate cancer that had progressed after hormonal therapy.Patients were treated with intravenous docetaxel at a dose of 25 mg/m2 (Day 1, 8, 15) plus carboplatin (AUC4, Day 1) every 4 weeks until they had either disease progression or unacceptable toxicity.The primary end point was prostate-specific antigen (PSA) response.Results: A total of 23 patients were evaluable for this study.The PSA partial objectiye response rate was 65.2% (15 patients).The median duration of PSA response was 7.8 months.Grade 3 leukopenia occurred in only 8.7% of patients.No grade 4 adverse events were admitted in this study.Conclusions: The combination chemotherapy using carboplatin and weekly docetaxel was effective without severe toxicity in patients with metastatic HRPC.